UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized, double-blind clinical trial

Diabetes care, 2015-03, Vol.38 (3), p.365-372

2015

Volltextzugriff (PDF)

Faster Aspart Versus Insulin Aspart as Part of a Basal-Bolus Regimen in Inadequately Controlled Type 2 Diabetes: The onset 2 Trial

Diabetes care, 2017-07, Vol.40 (7), p.951-957

2017

Volltextzugriff (PDF)

Type 2 Diabetes Mellitus Management in Canada: Is It Improving?

Canadian journal of diabetes, 2013-04, Vol.37 (2), p.82-89

2013

Volltextzugriff (PDF)

MEASURE: A proposed assessment framework for developing best practice recommendations for wound assessment

Wound repair and regeneration, 2004-05, Vol.12 (3 Suppl), p.S1-17

2004

Volltextzugriff (PDF)

Foot Care

Canadian journal of diabetes, 2013-04, Vol.37, p.S145-S149

2013

Volltextzugriff (PDF)

Inhaled insulin improves glycemic control when substituted for or added to oral combination therapy in type 2 diabetes: a randomized, controlled trial

Annals of internal medicine, 2005-10, Vol.143 (8), p.549

2005

Volltextzugriff (PDF)

Soins des pieds

Canadian journal of diabetes, 2013-10, Vol.37, p.S522-S527

2013

Volltextzugriff (PDF)

Response to Comment on Russell-Jones et al. Diabetes Care 2017;40:943-950. Comment on Bowering et al. Diabetes Care 2017;40:951-957

Diabetes care, 2018-03, Vol.41 (3), p.e29-e30

2018

Volltextzugriff (PDF)

Foot Care

Canadian journal of diabetes, 2018-04, Vol.42, p.S222-S227

2018

Volltextzugriff (PDF)

Abstract #1217 Baseline Nocturnal Glucose Change as a Predictor of Treatment Effect of Bolus Intensification in Insulintreated Type 2 Diabetes

Endocrine practice, 2018-04, Vol.24, p.313-314

2018

Volltextzugriff (PDF)

Baseline nocturnal glucose change: A predictor of the treatment effect of bolus intensification in insulin‐treated type 2 diabetes

Diabetes, obesity & metabolism, 2019-07, Vol.21 (7), p.1752-1756

2019

Volltextzugriff (PDF)

Beyond Blood Pressure Control: The DESTINATION study

Canadian journal of diabetes, 2008, Vol.32 (4), p.329-329

2008

Volltextzugriff (PDF)

Soins des pieds

Canadian journal of diabetes, 2013-10, Vol.37, p.S522-S527

2013

Volltextzugriff (PDF)

L’insuline Faster Aspart vs insuline asparte en Basal-Bolus améliore la glycémie postprandiale chez des patients DT2 incontrôlés dans une étude en double-aveugle : étude Onset ® 2

Diabetes & metabolism, 2017-03, Vol.43 (2), p.A115

2017

Volltextzugriff (PDF)

CA-195 - L’insuline Faster Aspart vs insuline asparte en Basal-Bolus améliore la glycémie postprandiale chez des patients DT2 incontrôlés dans une étude en double-aveugle : étude Onset® 2

Diabetes & metabolism, 2017-03, Vol.43 (2), p.A115-A115

2017

Volltextzugriff (PDF)

Canadian Practice Assessment in Type 2 Diabetes

Canadian journal of diabetes, 2013-12, Vol.37 (6), p.433-433

2013

Volltextzugriff (PDF)

Investigating the Association Between Baseline Characteristics (HbA1c and Body Mass Index) and Clinical Outcomes of Fast-Acting Insulin Aspart in People with Diabetes: A Post Hoc Analysis

Diabetes therapy, 2019-02, Vol.10 (1), p.177-188

2019

Volltextzugriff (PDF)

Canadian Practice Assessment in Type 2 Diabetes

Canadian journal of diabetes, 2013-10, Vol.37, p.S4-S4

2013

Volltextzugriff (PDF)

The Impact of Baseline BMI and HbA1c on Glycemic Control After Treatment with Fast-Acting Insulin Aspart in Individuals with Type 2 Diabetes

Canadian journal of diabetes, 2017-10, Vol.41 (5), p.S55

2017

Volltextzugriff (PDF)

140 - The Impact of Baseline BMI and HbA1c on Glycemic Control After Treatment with Fast-Acting Insulin Aspart in Individuals with Type 2 Diabetes

Canadian journal of diabetes, 2017-10, Vol.41 (5), p.S55-S55

2017

Volltextzugriff (PDF)

Faster-Acting Insulin Aspart vs. Insulin Aspart in Basal-Bolus Therapy Improved Postprandial Glycemic Control in Uncontrolled T2D in the Onset® 2 Trial

Canadian journal of diabetes, 2016-10, Vol.40 (5), p.S57-S57

2016

Volltextzugriff (PDF)

156 - Faster-Acting Insulin Aspart vs. Insulin Aspart in Basal-Bolus Therapy Improved Postprandial Glycemic Control in Uncontrolled T2D in the Onset® 2 Trial

Canadian journal of diabetes, 2016-10, Vol.40 (5), p.S57-S57

2016

Volltextzugriff (PDF)

Evaluating the Management of Type 2 Diabetes in the Primary Care Setting Through a Novel Multi-Step Needs Assessment Process

Canadian journal of diabetes, 2013-10, Vol.37, p.S39-S39

2013

Volltextzugriff (PDF)

Liraglutide + Metformin Combination Therapy in Type 2 Diabetes: Clinical Benefits Associated with Early Use of Liraglutide and with Switching a Sulfonylurea for Liraglutide

Canadian journal of diabetes, 2012-10, Vol.36 (5), p.S46-S46

2012

Volltextzugriff (PDF)

Diabetic foot ulcers. Pathophysiology, assessment, and therapy

Canadian family physician, 2001-05, Vol.47 (5), p.1007-1016

Bowering, C K

2001

Volltextzugriff (PDF)

1 – 25 von 43

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(39)
Mit Volltextzugriff
(38)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Endocrinology & Metabolism
(16)
Life Sciences & Biomedicine
(15)
Science & Technology
(15)
Humans
(13)
Other
(10)
Aged
(7)
Female
(7)
Middle Aged
(7)
Diabetes
(6)
Gastroenterology And Hepatology
(6)
Male
(6)
Diabetes Mellitus, Type 2 - Drug Therapy
(5)
Insulin
(5)
Biological And Medical Sciences
(4)
Diabetes Mellitus, Type 2 - Blood
(4)
Glucose
(4)
Medical Sciences
(4)
Blood Glucose - Metabolism
(3)
Diabetes Mellitus
(3)
Drug Therapy
(3)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized, double-blind clinical trial

Faster Aspart Versus Insulin Aspart as Part of a Basal-Bolus Regimen in Inadequately Controlled Type 2 Diabetes: The onset 2 Trial

Type 2 Diabetes Mellitus Management in Canada: Is It Improving?

MEASURE: A proposed assessment framework for developing best practice recommendations for wound assessment

Foot Care

Inhaled insulin improves glycemic control when substituted for or added to oral combination therapy in type 2 diabetes: a randomized, controlled trial

Soins des pieds

Response to Comment on Russell-Jones et al. Diabetes Care 2017;40:943-950. Comment on Bowering et al. Diabetes Care 2017;40:951-957

Foot Care

Abstract #1217 Baseline Nocturnal Glucose Change as a Predictor of Treatment Effect of Bolus Intensification in Insulintreated Type 2 Diabetes

Baseline nocturnal glucose change: A predictor of the treatment effect of bolus intensification in insulin‐treated type 2 diabetes

Beyond Blood Pressure Control: The DESTINATION study

Soins des pieds

L’insuline Faster Aspart vs insuline asparte en Basal-Bolus améliore la glycémie postprandiale chez des patients DT2 incontrôlés dans une étude en double-aveugle : étude Onset ® 2

CA-195 - L’insuline Faster Aspart vs insuline asparte en Basal-Bolus améliore la glycémie postprandiale chez des patients DT2 incontrôlés dans une étude en double-aveugle : étude Onset® 2

Canadian Practice Assessment in Type 2 Diabetes

Investigating the Association Between Baseline Characteristics (HbA1c and Body Mass Index) and Clinical Outcomes of Fast-Acting Insulin Aspart in People with Diabetes: A Post Hoc Analysis

Canadian Practice Assessment in Type 2 Diabetes

The Impact of Baseline BMI and HbA1c on Glycemic Control After Treatment with Fast-Acting Insulin Aspart in Individuals with Type 2 Diabetes

140 - The Impact of Baseline BMI and HbA1c on Glycemic Control After Treatment with Fast-Acting Insulin Aspart in Individuals with Type 2 Diabetes

Faster-Acting Insulin Aspart vs. Insulin Aspart in Basal-Bolus Therapy Improved Postprandial Glycemic Control in Uncontrolled T2D in the Onset® 2 Trial

156 - Faster-Acting Insulin Aspart vs. Insulin Aspart in Basal-Bolus Therapy Improved Postprandial Glycemic Control in Uncontrolled T2D in the Onset® 2 Trial

Evaluating the Management of Type 2 Diabetes in the Primary Care Setting Through a Novel Multi-Step Needs Assessment Process

Liraglutide + Metformin Combination Therapy in Type 2 Diabetes: Clinical Benefits Associated with Early Use of Liraglutide and with Switching a Sulfonylurea for Liraglutide

Diabetic foot ulcers. Pathophysiology, assessment, and therapy

Suchergebnisse filtern